These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12098090)

  • 1. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.
    Kreuz W; Ettingshausen CE; Zyschka A; Oldenburg J; Saguer IM; Ehrenforth S; Klingebiel T
    Semin Thromb Hemost; 2002 Jun; 28(3):285-90. PubMed ID: 12098090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
    Lusher JM
    Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitor development in non-severe haemophilia across Europe.
    Fischer K; Iorio A; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Gilman EA; Hollingsworth R; Makris M;
    Thromb Haemost; 2015 Oct; 114(4):670-5. PubMed ID: 26293381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.
    Bray GL; Gomperts ED; Courter S; Gruppo R; Gordon EM; Manco-Johnson M; Shapiro A; Scheibel E; White G; Lee M
    Blood; 1994 May; 83(9):2428-35. PubMed ID: 8167332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
    Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
    J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.
    Strauss T; Lubetsky A; Ravid B; Bashari D; Luboshitz J; Lalezari S; Misgav M; Martinowitz U; Kenet G
    Haemophilia; 2011 Jul; 17(4):625-9. PubMed ID: 21299743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review.
    Franchini M; Tagliaferri A; Mengoli C; Cruciani M
    Crit Rev Oncol Hematol; 2012 Jan; 81(1):82-93. PubMed ID: 21277222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.
    Ettingshausen CE; Kreuz W
    Haemophilia; 2006 Dec; 12 Suppl 6():102-6. PubMed ID: 17123402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development.
    Lusher JM
    Semin Thromb Hemost; 2002 Jun; 28(3):273-6. PubMed ID: 12098088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia.
    Batorova A; Jankovicova D; Morongova A; Bubanska E; Prigancova T; Horakova J; Machyniakova M; Cervenka J; Chandoga J; Böhmer D; Mistrik M
    Semin Thromb Hemost; 2016 Jul; 42(5):550-62. PubMed ID: 27235830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.
    Scharrer I; Bray GL; Neutzling O
    Haemophilia; 1999 May; 5(3):145-54. PubMed ID: 10444280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.
    Mancuso ME; Mannucci PM; Rocino A; Garagiola I; Tagliaferri A; Santagostino E
    J Thromb Haemost; 2012 May; 10(5):781-90. PubMed ID: 22452823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group.
    Goodeve AC; Williams I; Bray GL; Peake IR
    Thromb Haemost; 2000 Jun; 83(6):844-8. PubMed ID: 10896236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data.
    Yoshioka A; Fukutake K; Takamatsu J; Shirahata A;
    Int J Hematol; 2006 Aug; 84(2):158-65. PubMed ID: 16926139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation.
    Lusher J; Abildgaard C; Arkin S; Mannucci PM; Zimmermann R; Schwartz L; Hurst D
    J Thromb Haemost; 2004 Apr; 2(4):574-83. PubMed ID: 15102011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
    Gouw SC; van den Berg HM
    Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.
    Batlle J; Gómez E; Rendal E; Torea J; Lourés E; Couselo M; Vila P; Sedano C; Tusell X; Magallón M; Quintana M; González-Boullosa R; López-Fernández MF
    Ann Hematol; 1996 May; 72(5):321-6. PubMed ID: 8645745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update.
    Franchini M; Coppola A; Rocino A; Santagostino E; Tagliaferri A; Zanon E; Morfini M;
    Semin Thromb Hemost; 2013 Oct; 39(7):752-66. PubMed ID: 24022806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven.
    Johannessen M; Andreasen RB; Nordfang O
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):239-42. PubMed ID: 10870803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.
    Goudemand J; Rothschild C; Demiguel V; Vinciguerrat C; Lambert T; Chambost H; Borel-Derlon A; Claeyssens S; Laurian Y; Calvez T;
    Blood; 2006 Jan; 107(1):46-51. PubMed ID: 16166584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.